Updated: Vivek Ramaswamy drops out of presidential race, endorses Trump, no plans to return to Roivantnews2024-01-16T12:12:42+00:00January 16th, 2024|Endpoints News|
German trade union IG BCE opposes Bayer’s business split proposalnews2024-01-16T11:49:32+00:00January 16th, 2024|Endpoints News|
AbbVie-backed Disco raises €20M seed round to advance cancer cell mapping technologynews2024-01-16T08:30:11+00:00January 16th, 2024|Endpoints News|
CNS biotech Alto Neuroscience files for NYSE listingnews2024-01-15T14:02:59+00:00January 15th, 2024|Endpoints News|
Four buyouts (and one rumor that didn’t materialize); Isomorphic Labs’ first pharma deals; A CAR-T IPO; #JPM24 highlights; and morenews2024-01-13T11:00:09+00:00January 13th, 2024|Endpoints News|
Kyverna Therapeutics is considering a February IPO, according to people familiar with its plansnews2024-01-13T00:31:07+00:00January 13th, 2024|Endpoints News|
BioMarin’s chief commercial officer stepping down, search for successor beginsnews2024-01-12T20:31:32+00:00January 12th, 2024|Endpoints News|
PhRMA, Eli Lilly, other drug companies push back on FDA’s draft guidance about communicating off-label usenews2024-01-12T20:20:29+00:00January 12th, 2024|Endpoints News|
Economists, health policy experts say J&J’s IRA arguments are ‘overly simplistic’news2024-01-12T19:25:07+00:00January 12th, 2024|Endpoints News|
Evaluate buys forecasting group to build out prediction software and servicesnews2024-01-12T19:14:56+00:00January 12th, 2024|Endpoints News|
